82
Participants
Start Date
February 10, 2016
Primary Completion Date
March 27, 2023
Study Completion Date
March 27, 2023
Tagraxofusp Injection
Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.
Weill Cornell Medical Center, New York
Roswell Park Cancer Institute, Buffalo
Georgia Cancer Center at Augusta University, Augusta
Mayo Clinic Florida, Jacksonville
Norton Cancer Institute, Louisville
The Ohio State University, Columbus
Cleveland Clinic Foundation, Cleveland
Indiana Blood and Bone Marrow Transplantation, Indianapolis
University of Michigan Health System, Ann Arbor
Mayo Clinic, Rochester
Rush University Medical Center, Chicago
University of Kansas Cancer Center, Westwood
MD Anderson Cancer Center, Houston
Huntsman Cancer Institute, Salt Lake City
University of New Mexico, Albuquerque
University of California, Los Angeles, Los Angeles
City of Hope, Duarte
University of California, San Francisco, Clovis
Stanford Cancer Institute, Stanford
Dana Farber Cancer Institute (DFCI), Boston
Massachusetts General Hospital, Boston
John Theurer Cancer Center, Hackensack
University of Alberta, Edmonton
Princess Margaret Cancer Centre, Toronto
Stemline Therapeutics, Inc.
INDUSTRY